Skip to content

Study · Animal study (in vivo) · mouse · 2001

8 results

Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues.

Lall S, Tung LY, Ohlsson C, Jansson JO, Dickson SL

Biochemical and biophysical research communications1 Jan 2001Cited by 49 (Europe PMC)

PMID11162489 (opens in a new tab)DOI10.1006/bbrc.2000.4065 (opens in a new tab)PepBankPUB-11162489
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In GH-intact (+/lit) and GH-deficient (lit/lit) mice, ipamorelin induced a small (15%) increase in body weight by 2 weeks that was not increased further by 9 weeks.

    In plain wordsIn mice, ipamorelin caused a small rise in body weight within 2 weeks. The rise did not grow further by 9 weeks.

    Peptide
    Ipamorelin
    Outcome
    IncreaseBody weight at 2 and 9 weeks
    Study

    mousen: not reported in source

    GH-deficient (lit/lit) and GH-intact (+/lit, +/+) mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 2 and 9 weeksAs given in this study (mouse).

    Measurements

    Body weight increase
    15%
    +/lit and lit/lit mice, ipamorelin, 2 weeks

    Source sentences

    Summary
    In +/lit and lit/lit mice ipamorelin induced a small (15%) increase in body weight by 2 weeks, that was not further augmented by 9 weeks.
    1 context sentence
    Summary · context
    Here we compared the effects of twice daily s.c. treatment of GH and the GHS, ipamorelin, on body fat in GH-deficient (lit/lit) and in GH-intact (+/lit and +/+) mice.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In GH-deficient (lit/lit) and GH-intact (+/lit) mice, ipamorelin increased fat pad weights relative to body weight.

    In plain wordsIn mice, ipamorelin increased the weight of fat pads compared with body weight.

    Peptide
    Ipamorelin
    Outcome
    IncreaseFat pad weights relative to body weight
    Study

    mousen: not reported in source

    GH-deficient (lit/lit) and GH-intact (+/lit, +/+) mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneousAs given in this study (mouse).

    Source sentences

    Summary
    Ipamorelin also increased fat pad weights relative to body weight in both lit/lit and +/lit mice.
    1 context sentence
    Summary · context
    Here we compared the effects of twice daily s.c. treatment of GH and the GHS, ipamorelin, on body fat in GH-deficient (lit/lit) and in GH-intact (+/lit and +/+) mice.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In GH-intact mice, 2 weeks of GHRP‑6 treatment increased relative body fat measured by DEXA.

    In plain wordsIn mice with intact growth hormone, two weeks of GHRP‑6 raised the share of body fat.

    Peptide
    GHRP-6
    Outcome
    IncreaseRelative body fat by DEXA
    Study

    mousen: not reported in source

    GH-intact mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 2 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Two weeks GHS treatment (ipamorelin or GHRP-6) also increased relative body fat, quantified by in vivo dual energy X-ray absorpiometry (DEXA) in GH-intact mice.
    1 context sentence
    Summary · context
    Here we compared the effects of twice daily s.c. treatment of GH and the GHS, ipamorelin, on body fat in GH-deficient (lit/lit) and in GH-intact (+/lit and +/+) mice.

Studies that did not test the peptide alone5

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 04AnimalNot a test of Ipamorelin aloneAnimal study (in vivo)Efficacy outcome

    In GH-intact mice, two weeks of treatment with a GH secretagogue (ipamorelin or GHRP-6) increased relative body fat measured by DEXA.

    In plain wordsIn mice with normal growth hormone, two weeks of treatment with a growth hormone secretagogue (ipamorelin or GHRP-6) increased the share of body fat.

    Peptide
    Ipamorelin
    Outcome
    IncreaseRelative body fat by DEXA
    Study

    mousen: not reported in source

    GH-deficient (lit/lit) and GH-intact (+/lit, +/+) mice
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Two weeks GHS treatment (ipamorelin or GHRP-6) also increased relative body fat, quantified by in vivo dual energy X-ray absorpiometry (DEXA) in GH-intact mice.
    1 context sentence
    Summary · context
    Here we compared the effects of twice daily s.c. treatment of GH and the GHS, ipamorelin, on body fat in GH-deficient (lit/lit) and in GH-intact (+/lit and +/+) mice.

    In this study, Ipamorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Ipamorelin.

  2. 05AnimalNot a test of Ipamorelin aloneAnimal study (in vivo)Efficacy outcome

    In GH-intact mice, treatment with a GH secretagogue (not GH) increased serum leptin.

    In plain wordsIn mice with normal growth hormone, treatment with a growth hormone secretagogue raised blood leptin; growth hormone itself did not.

    Peptide
    Ipamorelin
    Outcome
    IncreaseSerum leptin
    Study

    mousen: not reported in source

    GH-deficient (lit/lit) and GH-intact (+/lit, +/+) mice
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Treatment with GHS, but not GH, increased serum leptin and food intake in GH-intact mice.
    1 context sentence
    Summary · context
    Here we compared the effects of twice daily s.c. treatment of GH and the GHS, ipamorelin, on body fat in GH-deficient (lit/lit) and in GH-intact (+/lit and +/+) mice.

    In this study, Ipamorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Ipamorelin.

  3. 06AnimalNot a test of Ipamorelin aloneAnimal study (in vivo)Efficacy outcome

    In GH-intact mice, treatment with a GH secretagogue (not GH) increased food intake.

    In plain wordsIn mice with normal growth hormone, treatment with a growth hormone secretagogue increased food intake; growth hormone itself did not.

    Peptide
    Ipamorelin
    Outcome
    IncreaseFood intake
    Study

    mousen: not reported in source

    GH-deficient (lit/lit) and GH-intact (+/lit, +/+) mice
    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    Treatment with GHS, but not GH, increased serum leptin and food intake in GH-intact mice.
    1 context sentence
    Summary · context
    Here we compared the effects of twice daily s.c. treatment of GH and the GHS, ipamorelin, on body fat in GH-deficient (lit/lit) and in GH-intact (+/lit and +/+) mice.

    In this study, Ipamorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Ipamorelin.

  4. 07AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome

    In GH-intact mice, treatment with GH secretagogues as a class, but not GH, increased serum leptin.

    In plain wordsIn mice with intact growth hormone, growth hormone secretagogues as a group raised leptin; growth hormone did not.

    Peptide
    GHRP-6
    Outcome
    IncreaseSerum leptin
    Study

    mousen: not reported in source

    GH-intact mice
    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    Treatment with GHS, but not GH, increased serum leptin and food intake in GH-intact mice.
    1 context sentence
    Summary · context
    Here we compared the effects of twice daily s.c. treatment of GH and the GHS, ipamorelin, on body fat in GH-deficient (lit/lit) and in GH-intact (+/lit and +/+) mice.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  5. 08AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome

    In GH-intact mice, treatment with GH secretagogues as a class, but not GH, increased food intake.

    In plain wordsIn mice with intact growth hormone, growth hormone secretagogues as a group increased food intake; growth hormone did not.

    Peptide
    GHRP-6
    Outcome
    IncreaseFood intake
    Study

    mousen: not reported in source

    GH-intact mice
    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    Treatment with GHS, but not GH, increased serum leptin and food intake in GH-intact mice.
    1 context sentence
    Summary · context
    Here we compared the effects of twice daily s.c. treatment of GH and the GHS, ipamorelin, on body fat in GH-deficient (lit/lit) and in GH-intact (+/lit and +/+) mice.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 3 to 36Current

    28 Oct 2026, 02:02 UTC

    The same notice was added 34 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.

    Study results updated

  2. Version 2

    9 Oct 2026, 03:13 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.